Immunotherapy Drugs Market Size and Share Evolution to 2026 by Growth Insight, New Development, Emerging Trends by GlaxoSmithKline, F. Hoffmann-La Roche AG, AbbVie, Merck, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Novartis International AG, AstraZeneca plc and Johnson & Johnson. etc

Immunotherapy, also called biologic therapy, is a cancer treatment that enhances the body’s natural defenses to fight off cancer cells. In this therapy, the substance made by body or in laboratory to improve, restore, or target immune system function is used. Moreover, some immunotherapies that reduce or suppress the immune response are known as suppression immunotherapies. Cell-based therapies such as dendritic cells, includingmacrophages, natural killer cells, lymphocytes, cytotoxic T lymphocytes (CTL) are used certain types of cancer. These cells effectively protect the body against cancer by aiming for abnormal antigens involved on the façade of the tumor cells. Furthermore, therapies such as cellular membrane from bacteria are used for medical purpose. Some of the others such as IL-7, IL-2, IL-12, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans, and a variety of chemokines are involved in preclinical and clinical studies.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/525

Increasing incidences of cancer and autoimmune diseases coupled with increasing demand for immunotherapy drugs is likely to support the market growth. Moreover, with increasing need for mAbs, the global immunotherapy drugs market is expected to witness significant growth during forecast period 2016-2024. The mAbs have a high attraction towards typical disease cells as well as areas that require treatment. Therefore, they can be used for therapies such as antibody-directed enzyme pro drug therapy and radio immunotherapy. Increasing use of these antibodies in the drug development processes is expected to drive the global immunotherapy drugs market growth during the forecast period.

Moreover, materialization of biosimilars is another factor driving growth of the global immunotherapy drugs market. Unlike generic drugs that have active pharmaceutical substance, biosimilars are almost identical to their creator biologic compounds. In fact, biosimilars are less expensive and assist in management of diseases and are more reachable for the patients than biologics. Furthermore, the sale of biosimilars among patients and hospitals is expected to increase significantly during the forecast period thereby supporting growth of the global immunotherapy drugs market.

Get Discount For First Time Buyers
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/525

Global Immunotherapy Drugs Market Taxonomy

On the basis of product type,

• Vaccines
• mAbs
• Non-specific immunotherapies
• Immune checkpoint inhibitors

On the basis of therapy area,

• Cancer
• Autoimmune and Inflammatory Diseases
• Infectious Diseases
• Other Therapy Areas

On the basis of therapy area, the cancer segment held the largest market share in 2016. This is owing to increasing use of immunotherapy as a first line of treatment in cancer. Furthermore, on the basis of product type, the mAbs segment accounted for the largest market share. Continuous improvement in new drugs coupled with entry of new molecules such as elotuzumab, obinutuzumab, zanolimumab, and onartuzumab into the market is expected to propel growth of the global immunotherapy drugs market during the forecast period.

Increasing prevalence of cancer and rise in demand from the Asia Pacific region is expected to drive global immunotherapy drugs market growth

According to National Cancer Institute, around 1,685,210 new cases of cancer are expected to be diagnosed in the U.S. in 2016. Furthermore, according to the same source, about 595,690 people are expected to die from the disease. As immunotherapy is used as a first line of treatment in the management of cancer the corresponding market is expected to expand significantly. Among regions, North America holds the largest share the global immunotherapy drugs market and is expected to retain its dominance over the forecast period. Asia Pacific is expected to be the fastest-growing market during the forecast period. This is owing to low cost of manufacturing of drugs and rising occurrence of cancer coupled with favorable regulatory framework in the region.

Major players operating in the global immunotherapy drugs market in the current scenario are GlaxoSmithKline, F. Hoffmann-La Roche AG, AbbVie, In., Merck & Co., Inc. Amgen, Inc., Bristol-Myers Squibb, Eli Lilly and Company, Novartis International AG, AstraZeneca plc and Johnson & Johnson.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.